BioHarvest Sciences (NASDAQ:BHST) Coverage Initiated at Maxim Group

Equities research analysts at Maxim Group assumed coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a report issued on Wednesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price would indicate a potential upside of 93.55% from the company’s previous close.

Separately, HC Wainwright started coverage on BioHarvest Sciences in a report on Friday, December 6th. They issued a “buy” rating and a $14.00 target price on the stock.

BioHarvest Sciences Stock Performance

Shares of NASDAQ:BHST opened at $6.20 on Wednesday. BioHarvest Sciences has a 52-week low of $6.09 and a 52-week high of $7.70. The company has a market capitalization of $101.84 million and a price-to-earnings ratio of -4.96.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.